PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11291202

Naproxen availability from variable-dose and weight sustained-release tablets.

M H Amaral·J M Lobo·D C Ferreira
View original source ↗Export metadata ↓

Abstract

The aim of this work was to compare the naproxen availability from hydroxypropyl methylcellulose (HPMC) matrix tablets containing the same dose and a 2-fold weight variation (160 mg of naproxen in tablets weighting 250 and 500 mg) or with the same weight and a 2-fold dose variation (500 mg of weight and 160 or 320 mg of naproxen). The 2-fold weight variation in tablets with the same dose and also the 2-fold dose variation in tablets with the same weight did not affect the naproxen release. In addition, the release rate of two tablets of the same formulation and one tablet with a 2-fold dose and weight variation was not significantly different at the first minutes of the dissolution assay.

Explore related subjects

Anti-Inflammatory Agents, Non-SteroidalBiological AvailabilityChemistry, PharmaceuticalDelayed-Action PreparationsLactoseMethylcelluloseNaproxenOxazinesParticle SizeTabletsJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M H Amaral, J M Lobo, D C Ferreira. 2001. Naproxen availability from variable-dose and weight sustained-release tablets.. https://doi.org/10.1081/ddc-100000240

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents.

The synthesis and biological evaluation of a new family of diterpenes, represented by structures 2 and 3, is presented. These compounds constitute isomeric analogues of acanthoic acid (1) and were examined as potent anti-inflammatory agents. Among them, methyl ester 12 exhibited a low non-specific cytotoxicity, inhibited TNF-alpha synthesis and displayed good specificity in suppressing cytokine expression.

Anti-Inflammatory Agents, Non-Steroidal↗
PubMed2003

Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.

Cyclooxygenase-2 (COX-2) is involved in diverse processes such as inflammation, carcinogenesis and apoptosis. As COX-2 inhibitors interfere with these processes, inhibition of COX-2 has been suggested as a promising anticancer treatment. However, the role of COX-2 in modulation of apoptosis as well as the death pathways affected by COX-2 inhibitors are poorly characterized. Here we demonstrate that the selective COX-2 inhibitors NS-398 and nimesulide increased TNF sensitivity of TNF-resistant HeLa H21 and TNF-sensitive HeLa D98 cells, although this cytokine induced significant COX-2 activity, as judged by prostaglandin E(2) (PGE(2)) production, only in H21 cells. TNF did also not induce PGE(2) production in MCF-7/casp-3 cells stably expressing COX-2; however, nimesulide strongly enhanced TNF-induced apoptosis in these cells. Furthermore, COX-2 activity in HeLa H21 cells could be inhibited by NS-398 concentrations that were 10 000-fold lower compared to those required for the induction of cell death. Most intriguingly, sensibilization to apoptosis was specifically observed in response to activation of death receptors. Not only TNF-induced cell death but also apoptosis triggered by the CD95 and TRAIL receptors was enhanced by nimesulide. In contrast, apoptosis induced by the anticancer drugs doxorubicine and etoposide that target the mitochondrial death pathway remained unaffected. Together, our data suggest that COX-2 inhibitors overcome apoptosis resistance and selectively sensitize tumor cells to the extrinsic death receptor-induced apoptotic pathway independently of COX-2.

Anti-Inflammatory Agents, Non-Steroidal↗